Clinical Trial Update: Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a conversion therapy combining RC48 (disitamab vedotin), sintilimab, and SOX (S-1 and oxaliplatin) for HER2 1+/2+ unresec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• RC48 (disitamab vedotin)
• S-1 (tegafur/gimeracil/oteracil)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Gastric Cancer | Phase 2 | Status: RECRUITING